Bridging Innovation and Access in HR-Positive/HER2-Negative Metastatic Breast Cancer: Implications for Managed Care

Program Description

As the most prevalent breast cancer subtype, accounting for approximately 70% of all cases, hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (MBC) remains a critical challenge, with a 5-year relative survival rate of approximately 36.5% for distant disease. A need for therapies to overcome primary and acquired endocrine resistance and prevent tumor relapse has contributed to the rapidly evolving treatment landscape. However, the introduction of novel therapies presents significant complexities for formulary development and resource utilization. This session provides managed care professionals and oncology pharmacists with the latest therapeutic strategies in HR+/HER2– MBC and their implications for patient care and formulary management. Expert faculty will discuss the critical role of biomarker testing in guiding individualized treatment sequencing across multiple lines of therapy. The pharmacology, clinical evidence, and appropriate use of novel agents, including CDK4/6 inhibitors, oral selective estrogen receptor degraders (SERDs), PIK3CA/AKT1/PTEN inhibitors, PARP inhibitors, and antibody-drug conjugates (ADCs) will be explored alongside strategies to navigate treatment selection among approved agents, optimize resource utilization, ensure appropriate genomic testing, and improve patient access to novel therapies within the managed care environment.

Target Audience: Managed Care Pharmacist, Oncology Pharmacist

Type of Activity: Application
Release date: November 7, 2025
Expiration date: November 7, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Interpret current guideline recommendations and biomarker testing strategies to support individualized treatment planning in HR-positive/HER2-negative (HR+/HER2–) metastatic breast cancer.
• Analyze efficacy and safety data from recent clinical trials assessing novel agents and combination regimens in the first line setting for HR+/HER2– metastatic breast cancer.
• Explain the role of novel targeted therapies in the treatment continuum beyond progression on CDK4/6 inhibitors for HR+/HER2– disease.
• Investigate the impact of evolving clinical evidence on formulary decision-making, value-based pathway development, and care optimization strategies for HR+/HER2– metastatic breast cancer.